ClinicalTrials.gg
RecruitingNCT07261631Updated Oct 9, 2026

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

A Phase 1 interventional study of 68Ga-NNS309 and 177Lu-DFC413 in Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer and HR+/HER2- Ductal and Lobular Breast Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 9 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 9, 2026First site in United StatesEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 7 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Planned enrollment
26th of 92
180 · median 91
Started
2025
the only one that year
Phase 1
34 of 101
6 open now
Primary completion
2029-05
later than 10 of 14 live
Registered
97th of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 26th largest by planned enrollment of the 92 interventional ones that give a count, is the only one that started in 2025, is one of 34 in phase 1, reaches primary completion later than 10 of the 14 other live ones, and was the 97th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Read the detailed description

GCJ904A12101 is first-in-human (FIH), phase I, open label study that consists of a dose escalation part followed by a dose expansion part. In both parts of the study, patients will initially be imaged with a 68Ga-NNS309 positron emission tomography (PET)/ computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan and will be evaluated for eligibility for 177Lu-DFC413 treatment. Patients eligible for treatment will receive 177Lu-DFC413. In the escalation part, different doses of 177Lu-DFC413 will be tested to assess its safety, tolerability, and dosimetry and identify the recommended radioactive administered dose(s) (RD(s)) for further evaluation. The expansion will include arms based on tumor type. The end of study will occur when all patients per disease group in the expansion part have completed the follow-up for disease progression or discontinued from the study for any reason, and all patients have completed treatment and the long-term follow-up period.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
  • Non-Small Cell Lung Cancer
  • HR+/HER2- Ductal and Lobular Breast Cancer
  • Triple Negative Breast Cancer
  • Colorectal Cancer
  • Soft Tissue Sarcoma

Keywords

  • PDAC
  • NSCLC
  • Breast cancer
  • CRC
  • STS
  • Radioligand therapy (RLT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years with one of the following indications:
  • Locally advanced unresectable or PDAC, with disease progression following, or intolerance to cytotoxic therapy, unless patient was ineligible to receive such therapy
  • Locally advanced unresectable or metastatic NSCLC without any actionable genomic alterations with disease progression following, or intolerance to chemotherapy and immunotherapy, unless patient was ineligible to receive such therapy, or locally advanced unresectable or metastatic NSCLC with an actionable genomic alteration with disease progression following, or intolerance to chemotherapy and targeted therapy, unless patient was ineligible to receive such therapy
  • Locally advanced unresectable or metastatic HR+/- ductal and lobular breast cancer with disease progression following, or intolerance to, hormone therapy and CDK inhibitor, and at least one additional , unless patient was ineligible to receive such therapy
  • Locally advanced unresectable or metastatic triple negative breast cancer (TNBC) with disease progression following, or intolerance to, at least two lines of therapy, unless patient was ineligible to receive such therapy
  • Locally advanced or metastatic unresectable CRC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy. Patients with known microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status must also have had disease progression following, or intolerance to, therapy, unless patient was ineligible to receive such therapy
  • (Dose expansion only) Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi) with disease progression following, or intolerance to, at least one line of systemic therapy
  • Patients must have lesions showing 68Ga-NNS309 uptake

Exclusion criteria

Exclusion Criteria:

  • (ANC) \< 1.5 x 109/L, \< 9 g/dL, or count \< 100 x 109/L
  • corrected by Fridericia's formula (QTcF) ≥ 470 msec
  • \< 60 mL/min/1.73m2, calculated using CKD-EPI 2021 or measured
  • Unmanageable urinary tract obstruction or urinary incontinence
  • Presence of symptomatic , or CNS metastases that require local CNS-directed therapy
  • Any prior radioligand therapy
  • Radiation therapy within 4 weeks prior to the first dose of [177Lu]Lu-DFC413

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Patients will receive 68Ga-NNS309 and only patients with tumor uptake will receive 177Lu-DFC413

    Drug: 68Ga-NNS309 · Drug: 177Lu-DFC413

Interventions

  • Drug68Ga-NNS309

    Diagnostic investigational radiopharmaceutical

  • Drug177Lu-DFC413

    Therapeutic investigational radiopharmaceutical

06

What researchers measure

Primary outcomes

  1. Incidence and severity of dose limiting toxicities of 177Lu-DFC413

    A dose limiting toxicity (DLT) is defined as any adverse event or abnormal laboratory value of CTCAE (version 5.0) Grade 3 or higher that occurs within the DLT evaluation period and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with a few exceptions defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not Grade 3 or higher.

    Time frame: Within first treatment cycle, up to maximum 6 weeks

  2. Incidence and severity of adverse events and serious adverse events of 177Lu-DFC413

    The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs) and Serious Adverse Event (TESAEs) and through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From study treatment start up to approximately 42 months

  3. Dose modifications for 177Lu-DFC413

    Dose modifications (dose interruptions and reductions) for 177Lu-DFC413 will be assessed and summarized using descriptive statistics. The number of patients with dose modification and the reasons will be summarized by treatment groups.

    Time frame: From study treatment start until last dose of study treatment, assessed up to approximately 24 weeks

  4. Dose intensity for 177Lu-DFC413

    Dose intensity for 177Lu-DFC413 will be assessed and summarized using descriptive statistics. Dose intensity is computed as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: From study treatment start until last dose of study treatment, assessed up to approximately 24 weeks

Secondary outcomes

  1. Overall response rate (ORR)

    ORR is defined as the proportion of patients with a BOR of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.

    Time frame: From study treatment start up to 6 months

  2. Duration of Response (DOR)

    DOR is the time between the first documented response (CR or PR) and the date of progression according to RECIST v1.1 guidelines, or death due to any cause.

    Time frame: From study treatment start up to 6 months

  3. Disease control rate (DCR)

    DCR is defined as the proportion of patients with a BOR of CR, PR or stable disease according to RECIST v1.1 guidelines.

    Time frame: From study treatment start up to 6 months

  4. Progression free survival (PFS)

    PFS is defined as the time from the date of start of treatment to the date of the first documented progression according to RECIST v1.1 guidelines or death due to any cause.

    Time frame: From study treatment start up to 6 months

  5. Area Under the Curve (AUC) of 177Lu-DFC413

    The 177Lu-DFC413 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. AUC will be determined by non-compartmental methods.

    Time frame: Up to 8 days after first dose

  6. Total body clearance of 177Lu-DFC413

    The 177Lu-DFC413 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Total body clearance will be determined by non-compartmental methods.

    Time frame: Up to 8 days after first dose

  7. Observed maximum blood concentration (Cmax) of 177Lu-DFC413

    The 177Lu-DFC413 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Cmax will be determined by non-compartmental methods.

    Time frame: Up to 8 days after first dose

  8. Observed maximum radioactivity concentration (Rmax) of 177Lu-DFC413

    The 177Lu-DFC413 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Rmax will be determined by non-compartmental methods.

    Time frame: Up to 8 days after first dose

  9. Volume of distribution (Vz) of 177Lu-DFC413 during the terminal phase

    The 177Lu-DFC413 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Vz will be determined by non-compartmental methods.

    Time frame: Up to 8 days after first dose

  10. Terminal elimination half-life (T1/2) of 177Lu-DFC413

    The 177Lu-DFC413 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. T1/2 will be determined by non-compartmental methods.

    Time frame: Up to 8 days after first dose

  11. Urinary excretion of radioactivity expressed as a percentage of injected dose (%ID)

    Urine elimination data for 177Lu-DFC413 will be assessed based on decay-corrected urine radioactivity concentration data. Urine elimination data will be expressed as percentage of injected dose (%ID).

    Time frame: Up to 3 days after first dose

  12. Renal clearance of 177Lu-DFC413

    Urine samples will be collected over specified time intervals and analyzed for radioactivity. Renal clearance of 177Lu-DCF413 will be summarized using descriptive statistics.

    Time frame: Up to 3 days after first dose

  13. Absorbed dose of 177Lu-DFC413

    Time activity curves (TACs) for the various organs and tumor lesions will be produced as fraction of injected activity per gram of tissue (%ID/g) as a function of time.

    Time frame: Up to 8 days after first dose

  14. Incidence and severity of adverse events and serious adverse events of [68Ga]Ga-NNS309

    The distribution of adverse events will be done via the analysis of frequencies for TEAEs and TESAEs and through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: Up to 3 days after administration

  15. Visual and quantitative assessment of [68Ga]Ga-NNS309 uptake in normal tissues and tumor lesions over time

    After \[68Ga\]Ga-NNS309 administration, \[68Ga\]Ga-NNS309 PET/CT or PET/MRI will be performed. Standardized uptake values (SUVs) of \[68Ga\]Ga-NNS309 in normal tissues and tumor lesions over time will be summarized.

    Time frame: Up to 3 days after administration

07

Study locations

9 of 9 sites recruiting
  • United Theranostics
    Princeton, New Jersey 08540, United States
    Recruiting
    • Jessica DeBerry · Contactjdeberry@unithera.com · +1 609 300 2858
    • Munir Ghesani · Principal investigator
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Novartis Investigative Site
    Odense C, 5000, Denmark
    Recruiting
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
  • Novartis Investigative Site
    Essen, 45147, Germany
    Recruiting
  • Novartis Investigative Site
    Haifa, 3109601, Israel
    Recruiting
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
    Recruiting
  • Novartis Investigative Site
    Singapore, 119228, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 168583, Singapore
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2029, 41 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 41 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 3, 2025
StartActual
Nov 24, 2025
Primary completionEst.
May 9, 2029
CompletionEst.
May 9, 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • United Theranostics · Princeton, United States
Oct 9, 2026
Eligibility
Maximum age 100 Years→none
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added — first site in United States
    Show site
    • United Theranostics · Princeton, United States
    Eligibility Maximum age 100 Years→none
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07261631
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Nov 24, 2025
Primary completion
May 9, 2029 (estimated)
Completion
May 9, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion